Multiple Sclerosis Implementation Network (Registry)

The Multiple Sclerosis Implementation Network (MSIN) is a collaboration between the Multiple Sclerosis Association of America (MSAA), The University of Texas Health Science Center at Houston (UTHealth Houston), Dell Medical School at The University of Texas at Austin, and Novartis Pharmaceuticals Corporation. The goal of MSIN is to improve Multiple Sclerosis (MS) care, patient health, and quality of life through the development and support of implementation research and clinical practice collaboration. MSIN brings together healthcare teams, people with MS, and research leaders in MS and implementation science (IS) to learn, share, test, implement, and disseminate innovations that improve MS care, patient health, and quality of life.

This ClinicalTrials.gov record pertains to the MSIN Patient Registry, which is a comprehensive database that integrates participants' electronic health records from various providers.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Multiple Sclerosis Autoimmune Diseases Autoimmune Diseases of the Nervous System Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Immune System Diseases Nervous System Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Multiple Sclerosis Association of America, Cherry Hill, New Jersey, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

diagnosed with Multiple Sclerosis
can speak and understand English comfortably

Treatment and study plan

Primary outcomes

Multiple sclerosis disability as assessed by the Patient-Determined Disease Steps (PDDS) Scale

Time frame: 5 years

Total score on the PDDS ranges from 0 (normal) to 8 (Bedridden: Unable to sit in a wheelchair for more than one hour), with a higher score indicating a worse outcome.
Perception of cognitive impairment as assessed by the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) Scale

Time frame: 5 years

Total score on the MSNQ ranges from 0 to 60, with a higher score indicating greater perceived cognitive impairment.

Study contacts

Contact information is provided by the study sponsor or research team.

Amanda Montague, EdM

CONTACT

[email protected]

800-532-7667

Sponsors and collaborators

Lead sponsor

The University of Texas Health Science Center, Houston

Other

Collaborators

Multiple Sclerosis Association of America
Novartis
The University of Texas at Austin

Registry information

Official study title

Multiple Sclerosis Implementation Network

Important dates

Study start: 2025
Primary completion: 2030
Study completion: 2030
First posted: Feb 17, 2026
Registry last updated: Feb 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting